Omnicell (NASDAQ:OMCL) Price Target Raised to $64.00 at Craig Hallum

Omnicell (NASDAQ:OMCL) had its price target raised by Craig Hallum from $45.00 to $64.00 in a research report report published on Thursday, Benzinga reports. The firm currently has a buy rating on the stock.

OMCL has been the subject of a number of other reports. Bank of America restated a “neutral” rating and issued a $57.00 price objective (up from $44.00) on shares of Omnicell in a report on Thursday. Benchmark reaffirmed a “buy” rating and set a $48.00 price objective on shares of Omnicell in a research report on Wednesday, October 9th. Wells Fargo & Company upped their target price on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research note on Monday, October 14th. JPMorgan Chase & Co. lifted their price target on shares of Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a research note on Friday, August 23rd. Finally, Barclays upgraded shares of Omnicell from an “underweight” rating to an “equal weight” rating and increased their price objective for the company from $26.00 to $39.00 in a research report on Friday, August 2nd. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $49.14.

Omnicell Stock Performance

OMCL stock traded down $0.10 during midday trading on Thursday, hitting $48.54. The company had a trading volume of 198,297 shares, compared to its average volume of 525,856. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 1.05. The stock’s 50 day moving average price is $43.26 and its 200 day moving average price is $35.17. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.74.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.37. Omnicell had a negative net margin of 1.66% and a positive return on equity of 2.55%. The company had revenue of $276.80 million during the quarter, compared to the consensus estimate of $254.41 million. During the same period in the prior year, the firm earned $0.29 earnings per share. Omnicell’s revenue was down 7.4% on a year-over-year basis. As a group, sell-side analysts expect that Omnicell will post 0.64 earnings per share for the current fiscal year.

Institutional Trading of Omnicell

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC raised its holdings in Omnicell by 248.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after purchasing an additional 1,000 shares during the period. GAMMA Investing LLC grew its stake in shares of Omnicell by 78.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after acquiring an additional 553 shares during the period. EntryPoint Capital LLC increased its holdings in Omnicell by 121.2% in the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock worth $72,000 after acquiring an additional 1,345 shares in the last quarter. CWM LLC raised its stake in Omnicell by 68.2% during the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after acquiring an additional 1,236 shares during the period. Finally, 1620 Investment Advisors Inc. lifted its holdings in Omnicell by 230.1% during the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after purchasing an additional 1,542 shares in the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.